drugset / Trial / NCT04232826
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of CNCT19 in adult patients with relapsed or refractory diffuse Non-Hodgkin lymphoma.
Timeline
- Start
- 2020-01-15
- Primary completion
- 2021-01-01
- Completion
- 2022-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CNCT19 | Cell therapy | 1e+08 cells | Intravenous |
| Subject | CNCT19 | Cell therapy | 2e+08 cells | Intravenous |
| Subject | CNCT19 | Cell therapy | 4e+08 cells | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |